We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.'s share was trading at $65.41 as of October 15th. DXCM’s trailing and forward P/E were 46.79 and 25.64 respectively according to Yahoo Finance.
Hunterbrook Media’s investigation reveals severe safety, operational, and financial concerns at Dexcom (DXCM), particularly surrounding its G7 continuous glucose monitor (CGM). After Dexcom secretly altered a key G7 sensor component in December 2023, internal studies showed the new...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.